Snapshot
Insulin glargine, marketed under the names Lantus among others, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a "peakless" profile (according to the insulin glargine package insert).
The Asia-Pacific Insulin Glargine market will reach xxx Million USD in 2018 and CAGR xx% 2018-2023. The report begins from overview of Industry Chain structure, and describes industry environment, then analyses market size and forecast of Insulin Glargine by product, region and application, in addition, this report introduces market competition situation among the vendors and company profile, besides, market price analysis and value chain features are covered in this report.
Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):
Single Dose Vial
Pre-filled Syringe
Company Coverage (Sales Revenue, Price, Gross Margin, Main Products etc.):
Sanofi-Aventis
Ganlee
Biocon
Application Coverage (Market Size & Forecast, Different Demand Market by Region, Main Consumer Profile etc.):
Treat type 1 diabetes
Treat type 2 diabetes
Region Coverage (Regional Production, Demand & Forecast by Regions etc.):
China
Japan & Korea
India
Southeast Asia
Oceania